Clinical trial · Interventional
Lymphoscintigraphy in Patients With Vaginal Cancer
Lymphoscintigraphy and Selective Lymphatic Mapping in Patients With Invasive Vaginal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary Objectives: 1. Determine the feasibility of using pretreatment lymphoscintigraphy to identify the sentinel lymph node(s) in patients with vaginal cancer dispositioned to receive radiation therapy. 2. Determine the feasibility of using preoperative lymphoscintigraphy and intraoperative lymphatic mapping to identify the sentinel lymph node(s) in patients with vaginal cancer dispositioned to undergo surgery and bilateral lymph node dissection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Vaginal Cancer | Malignant Vaginal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lymphoscintigraphy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Lymphoscintigraphy
- interventionNames
- Procedure: Lymphoscintigraphy
Primary outcomes (1)
- measure
- Identification of sentinel lymph node(s) in patients with vaginal cancer using lymphoscintigraphy and intraoperative lymphatic mapping.
- timeFrame
- Preoperative and intraoperative, prior to radiation therapy, data collection
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Patients must have invasive vaginal cancer, any histology, any stage. * Patients with prior excision of the primary are eligible. * Patients with recurrent vaginal cancer who have not had a prior inguinal or groin lymph node dissection. * Patients undergoing either surgical resection and assessment of inguinal or groin lymph nodes, radiation therapy and/or chemotherapy. * Patients must sign an IRB approved informed consent. Exclusion Criteria: * Known allergy to triphenylmethane compounds. * Pregnancy. * Prior radiation therapy to the vagina, vulva, groin or pelvis. * Prior inguinal, femoral or pelvic lymphadenectomy. * Patients who are not good surgical candidates.
References
Publications (1)
- RESULTFrumovitz M, Gayed IW, Jhingran A, Euscher ED, Coleman RL, Ramirez PT, Levenback CF. Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecol Oncol. 2008 Mar;108(3):478-81. doi: 10.1016/j.ygyno.2007.12.001. Epub 2008 Jan 10. PMID 18190952